This website uses cookies to improve the site and user experience. By continuing to browse this site,
you agree to accept our use of cookies. For more information, please review our Cookies Policy
ASCO® 2021
Presentations

Brentuximab Vedotin | Diffuse Large B-cell Lymphoma | Abstract TPS7571
Brentuximab Vedotin in Combination With Lenalidomide and Rituximab in Subjects With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL) (Trial in Progress)

Brentuximab Vedotin | Hodgkin Lymphoma | Abstract 7528
Brentuximab Vedotin with Chemotherapy in Adolescents and Young Adults (AYAs) With Stage III or IV Hodgkin Lymphoma: a Subgroup Analysis From the Phase 3 ECHELON-1 Study

Tucatinib | Breast Cancer | Abstract 1043
Updated Results of Tucatinib vs Placebo Added to Trastuzumab and Capecitabine for Patients With Pretreated HER2+ Metastatic Breast Cancer With and Without Brain Metastases (HER2CLIMB)

Tucatinib | Solid Tumors | Abstract TPS3151
SGNTUC-019: Phase 2 Basket Study of Tucatinib and Trastuzumab in Previously Treated Solid Tumors with HER2 Alterations (Trial in Progress)

Tucatinib | Breast Cancer | Abstract TPS1097
HER2CLIMB-04: Phase 2 Open Label Trial of Tucatinib + Trastuzumab Deruxtecan in Patients With HER2+ Unresectable Locally-Advanced or Metastatic Breast Cancer With and Without Brain Metastases (Trial in Progress)

Tisotumab Vedotin | Cervical Cancer | Abstract TPS5596
Tisotumab Vedotin vs Investigator’s Choice Chemotherapy in Second- or Third-Line Recurrent or Metastatic Cervical Cancer (innovaTV 301/ENGOT cx12/GOG 3057, Trial in Progress)

SGN-B6A | Solid Tumors | Abstract TPS3144
A Phase 1 Study of SGN-B6A, an Antibody-Drug Conjugate Targeting Integrin Beta-6, in Patients With Advanced Solid Tumors (SGNB6A-001, Trial in Progress)

SEA-TGT | Advanced Malignancies | Abstract TPS2657
SGNTGT-001: A Phase 1 Study of SEATGT, an Effector-Function Enhanced Monoclonal Antibody (mAb), in Advanced Malignancies (Trial in Progress)

Enfortumab Vedotin | Urothelial Carcinoma | Abstract 4528
Study EV-103: Update on Durability Results and Long Term Outcome of Enfortumab Vedotin + Pembrolizumab in First Line Locally Advanced or Metastatic Urothelial Carcinoma (la/mUC)

Enfortumab Vedotin | Urothelial Cancer | Abstract 4524
Enfortumab Vedotin in Cisplatin-Ineligible Patients With Locally Advanced or Metastatic Urothelial Cancer Who Received Prior PD-1/PD-L1 Inhibitors: An Updated Analysis of EV-201 Cohort 2

Enfortumab Vedotin | Urothelial Carcinoma | Abstract 4539
Quality of Life, Functioning, and Symptoms in Patients With Previously Treated Locally Advanced or Metastatic Urothelial Carcinoma From EV-301: A Randomized Phase 3 Trial of Enfortumab Vedotin vs Chemotherapy

Enfortumab Vedotin | Bladder Cancer | Abstract TPS4587
KEYNOTE-B15/EV-304: Randomized Phase 3 Study of Perioperative Enfortumab Vedotin Plus Pembrolizumab Versus Chemotherapy in Cisplatin-Eligible Patients with Muscle-Invasive Bladder Cancer (MIBC)